|
Exagen Inc
XGN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Exagen Inc growth rates, revenue grew
by 4.91 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1176
Medical Laboratories industry recorded
growth of revenues by 2.95 %
Exagen Inc net loss increased from $-3 millions, to $-4 millions in first quarter of 2025,
• More on XGN's Growth
|
|
Exagen Inc realized a net loss in trailing twelve months.
Exagen Inc realized cash reduction of $ -0.87 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 2.45.
Medical Laboratories industry's Price to Sales ratio is at 2.26.
• More on XGN's Valuation
|
|
|
|
|
Exagen Inc realized net loss in trailing twelve months.
Exagen Inc realized cash outflow of $ -0.87per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 2.45.
Medical Laboratories industry's Price to Sales ratio is at 2.26.
Exagen Inc Price to Book Ratio is at 21.33 lower than Industry Avg. of 329.32. and higher than S&P 500 Avg. of 0.01
• More on XGN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com